These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 37505487)

  • 1. Authority of Medicare to Limit Coverage of FDA-Approved Products: Legal and Policy Considerations.
    Daval CJR; Kesselheim AS
    JAMA Intern Med; 2023 Sep; 183(9):999-1004. PubMed ID: 37505487
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improving Food and Drug Administration-Centers for Medicare and Medicaid Services Coordination for Drugs Granted Accelerated Approval.
    Neumann PJ; Crummer E; Chambers JD; Tunis SR
    Milbank Q; 2023 Dec; 101(4):1047-1075. PubMed ID: 37644739
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Forcing isolation: Medicare's "in the home" coverage standard for wheelchairs.
    Medicare Rights Center
    Care Manag J; 2005; 6(1):29-37. PubMed ID: 16447855
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aligning US Agency Policies for Cardiovascular Devices Through the Breakthrough Devices Program.
    Moneer O; Rathi VK; Johnston JL; Ross JS; Dhruva SS
    JAMA Cardiol; 2023 Dec; 8(12):1174-1181. PubMed ID: 37878306
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Medicare covers the majority of FDA-approved devices and Part B drugs, but restrictions and discrepancies remain.
    Chambers JD; May KE; Neumann PJ
    Health Aff (Millwood); 2013 Jun; 32(6):1109-15. PubMed ID: 23733986
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Looking at CER from Medicare's perspective.
    Mohr P
    J Manag Care Pharm; 2012 May; 18(4 Suppl A):S5-8. PubMed ID: 22578211
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evidence supporting FDA approval and CMS national coverage determinations for novel medical products, 2005 through 2016: A cross-sectional study.
    Roginiel AC; Dhruva SS; Ross JS
    Medicine (Baltimore); 2018 Oct; 97(40):e12715. PubMed ID: 30290675
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Coverage of Novel Therapeutic Agents by Medicare Prescription Drug Plans Following FDA Approval.
    Shaw DL; Dhruva SS; Ross JS
    J Manag Care Spec Pharm; 2018 Dec; 24(12):1230-1238. PubMed ID: 30479199
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Medicare challenges and solutions--reimbursement issues in treating the patient with colorectal cancer.
    Kaa K
    J Manag Care Pharm; 2007 Aug; 13(6 Suppl C):S19-26. PubMed ID: 17713991
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Medicare is scrutinizing evidence more tightly for national coverage determinations.
    Chambers JD; Chenoweth M; Cangelosi MJ; Pyo J; Cohen JT; Neumann PJ
    Health Aff (Millwood); 2015 Feb; 34(2):253-60. PubMed ID: 25646105
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Medicare coverage for oncology services.
    Bagley GP; McVearry K
    Cancer; 1998 May; 82(10 Suppl):1991-4. PubMed ID: 9587095
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CHANGING FACE OF MEDICARE'S NATIONAL COVERAGE DETERMINATIONS FOR TECHNOLOGY.
    Chambers JD; Chenoweth MD; Pyo J; Cangelosi MJ; Neumann PJ
    Int J Technol Assess Health Care; 2015 Jan; 31(5):347-54. PubMed ID: 26750558
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Opacity and cost effectiveness analysis in Medicare coverage decisions: health policy encounters administrative law.
    Kolber MS
    Food Drug Law J; 2009; 64(3):515-30. PubMed ID: 19999645
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Private payers disagree with Medicare over medical device coverage about half the time.
    Chambers JD; Chenoweth M; Thorat T; Neumann PJ
    Health Aff (Millwood); 2015 Aug; 34(8):1376-82. PubMed ID: 26240252
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Medicare's national coverage decisions for technologies, 1999-2007.
    Neumann PJ; Kamae MS; Palmer JA
    Health Aff (Millwood); 2008; 27(6):1620-31. PubMed ID: 18997221
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Statutory Authority for Medicare Coverage Decisions-CMS Is an Independent Federal Agency.
    Crosson FX; Redberg RF
    JAMA Intern Med; 2023 Sep; 183(9):910-912. PubMed ID: 37505506
    [No Abstract]   [Full Text] [Related]  

  • 17. Spending by the Centers for Medicare & Medicaid Services Before and After Confirmation of Benefit for Drugs Granted US Food and Drug Administration Accelerated Approval, 2012 to 2017.
    Skydel JJ; Egilman AC; Wallach JD; Ramachandran R; Gupta R; Ross JS
    JAMA Health Forum; 2022 May; 3(5):e221158. PubMed ID: 35977252
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Baby doe redux? The Department of Health and Human Services and the Born-Alive Infants Protection Act of 2002: a cautionary note on normative neonatal practice.
    Sayeed SA
    Pediatrics; 2005 Oct; 116(4):e576-85. PubMed ID: 16199687
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bariatric surgery complications before vs after implementation of a national policy restricting coverage to centers of excellence.
    Dimick JB; Nicholas LH; Ryan AM; Thumma JR; Birkmeyer JD
    JAMA; 2013 Feb; 309(8):792-9. PubMed ID: 23443442
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Will CMS Find Aducanumab Reasonable and Necessary for Alzheimer Disease After FDA Approval?
    Schulman KA; Greicius MD; Richman B
    JAMA; 2021 Aug; 326(5):383-384. PubMed ID: 34279572
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.